Study: U.S.-Based Biotech, Pharma Firms Yield Greatest Shareholder Return

Source: Fortune

May 10, 2016

A new ranking by Boston Consulting Group (BCG) finds that, among global large-cap companies, U.S.-based biotech and pharmaceutical firms, on average, yield the greatest total shareholder return, reports Fortune.

Based on the metrics BCG followed, New York-based Regeneron Pharmaceuticals showed the largest return, and boasts an average 75.3% total shareholder return since 2011. Two other U.S. pharma firms that made the list in the top 10 global value creators included California-based Gilead Sciences and Cambridge, Massachusetts-based Biogen. The entire ranking by BCG can be found here.

You can read the full report from Fortune here.


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments